Article Figures & Data
Figures
- Figure 1
- Treatment algorithm for diabetic macular edema
Tables
- Table 1
- Reported cut-off values according to different optical coherence tomography (OCT) machines.
Machine Bentaleb-Machkour et al54 Cochrane review55 Brown et al56 Campbell et al57 Goebel et al58 Stratus OCT 197 μm 230 μm 300 μm 240μm NA Cirrus HD-OCT 254 μm 254 μm NA NA NA Spectralis HRA+OCT 236 μm 300 μm NA NA NA OCT 2000 scanner NA NA NA NA 230 μm OCT: optical coherence tomography, HRA: heidelberg retina angiograph
Study Drugs Study design Patient status Number (eyes) Follow-up (months) Mean number IVI Baseline VA (letters) Final VA (letters) Mean VA gain (letters) Mean CRT reduction IOP Cataract progression/extraction Bahrami et al91 Aflibercept Prospective Non-Naïve 43 6 5 67.8 71 3.2 37 μm 0% (IOP ≥25 mmHg or a rise of IOP ≥10 mmHg) 0% Kaiho et al92 Aflibercept ND Non-Naïve 51 12 3.8 65.5 70 4.5 ND ND ND Aksoy et al93 Bevacizumab Prospective Naïve 20 6 6 51 55.5 4.5 210 μm 10% (IOP >21 mmHg) 2.50% Fong et al94 Bevacizumab Retrospective Mixed (65% naive, 30% laser, 4% steroid) 309 24 3.1 57 62.3 5.3 ND ND ND Güler et al95 Bevacizumab Prospective ND 20 9 6 38 42 4 295 ± 42 μm ND 0% Koc et al96 Bevacizumab Retrospective Naïve 90 24 4.9 45.2 48.7 3.5 74.7 ± 133.9 ND 13.70% Riazi-Esfahani et al97 Bevacizumab ND Naïve 46 6 67.5 72.5 5 102 ± 108 6.5% (IOP ≥21 mmHg) 0 Cheema et al98 Bevacizumab (diffuse) Retrospective ND 28 6 1.3 44 45 1 ND ND ND Ciulla et al99 Ranibizumab Retrospective Non-Naïve 33 12 6 59 63 4 44 μm ND ND Egan et al100 Ranibizumab Retrospective Mixed (49.6% Naive) 3103 24 5.4 51.1 52.5 1.4 ND ND ND IVI: intravitreal injection, VA: visual acuity, CR: central retnal thickness, IOP: intra-ocular pressure, ND: not determined/detected
- Table 3
- Summary of real-life studies supporting the safety and efficacy of dexamethasone implants.
Study Study design Patient status Number (eyes) Follow-up (months) Mean number IVI Mean VA gain (letters) CRT reduction by OCT IOP Cataract progression/extraction Chatziralli et al110 Prospective Non-naive 54 12 2.1 5.2 181 μm 5.6% (IOP >20 mmHg) 4.30% Cicinelli et al108 Retrospective Non-naive 45 12 1.9 5.8 29 μm 18.4% (IOP ≥20 mmHg) 20% Iglicki et al111 Retrospective Non-naive 59 24 3.1 8.5 ND 7.10% ND Guigou et al112 Retrospective Mixed (20.5% de naive) 78 6 1.2 8.0 145.2 μm 11.7% (IOP >25 mmHg), 13.3% (rise of IOP >10 mmHg) 0% Pareja-Rios et al113 Retrospective Naive 113 12 1.4 9.7 32 μm 4% (rise of IOP >10 mmHg) ND Bellocq et al114 Prospective Mixed (73% naive) 37 6 1.5 10.1 206 μm 14% (IOP > 25 mmHg), 3% (IOP >35 mmHg) 8% (rise of IOP > 10 mmHg) ND Malcles et al115 Retrospective Mixed (27% naive) 128 36 3.6 9.5 138 μm 10.2% (IOP >25 mmHg), 2.3% (IOP >35 mmHg) 19% (rise of IOP >10 mmHg) ND Scaramuzzi et al116 Retrospective Mixed (7% naive) 15 12 2.0 8.5 240 μm 20% 8.30% IVI: intravitreal injection, VA: visual acuity, CRT: central retnal thickness, IOP: intra-ocular pressure, ND: not determined/detected, OCT: optical coherence tomography
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.